Related references
Note: Only part of the references are listed.Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Jeffrey S. Heier et al.
LANCET (2022)
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Charles C. Wykoff et al.
LANCET (2022)
Intravitreal injections: past trends and future projections within a UK tertiary hospital
Reena Chopra et al.
EYE (2022)
Next-generation anti-VEGF agents for diabetic macular oedema
Matias Iglicki et al.
EYE (2022)
Faricimab: First Approval
Matt Shirley
DRUGS (2022)
Faricimab: Two in the Bush Is Proving Better than One in the Hand?
Ashish Sharma et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2022)
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema
Muhammad Z. Chauhan et al.
CELLS (2022)
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
Charles C. Wykoff et al.
OPHTHALMOLOGY AND THERAPY (2022)
Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
Thales Antonio Cabral de Guimaraes et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2021)
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases
Massimo Nicolo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration
Ramin Tadayoni et al.
OPHTHALMOLOGICA (2021)
Factors Affecting a Short-Term Response to Anti-VEGF Therapy in Diabetic Macular Edema
Ayumi Usui-Ouchi et al.
LIFE-BASEL (2021)
Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data
Antonia M. Joussen et al.
EYE (2021)
Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats
Paulina Jakubiak et al.
MOLECULAR PHARMACEUTICS (2021)
New Insights in Resistant Diabetic Macular Edema
Dante Akira Kondo Kuroiwa et al.
OPHTHALMOLOGICA (2021)
Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives
Rita Flores et al.
OPHTHALMOLOGICA (2021)
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai
Igor Kozak et al.
PLOS ONE (2021)
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
Prem Patel et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
Arshad M. Khanani et al.
OPHTHALMOLOGY SCIENCE (2021)
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Marlena Surowka et al.
MABS (2021)
Abicipar pegol-a novel anti-VEGF therapy with a long duration of action
Elad Moisseiev et al.
EYE (2020)
Abicipar pegol: the non-monoclonal antibody anti-VEGF
Ashish Sharma et al.
EYE (2020)
Faricimab: expanding horizon beyond VEGF
Ashish Sharma et al.
EYE (2020)
Advancing a Stem Cell Therapy for Age-Related Macular Degeneration
Helen C. O'Neill et al.
CURRENT STEM CELL RESEARCH & THERAPY (2020)
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The AVENUE Phase 2 Randomized Clinical Trial
Jayashree Sahni et al.
JAMA OPHTHALMOLOGY (2020)
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The STAIRWAY Phase 2 Randomized Clinical Trial
Arshad M. Khanani et al.
JAMA OPHTHALMOLOGY (2020)
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
Majid Khan et al.
CELLS (2020)
The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye
Quan Dong Nguyen et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2020)
Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
Mine Esen Baris et al.
TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY (2020)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni et al.
OPHTHALMOLOGY (2019)
Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization
Richard H. Foxton et al.
EMBO MOLECULAR MEDICINE (2019)
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
Rehan M. Hussain et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Brolucizimab—leading an era of structural revolution for long-term VEGF suppression
Ashish Sharma et al.
EYE (2019)
Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia
Kimberly L. Spooner et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources
Vincent Daien et al.
BMC OPHTHALMOLOGY (2019)
Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials
Rahul N. Khurana et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Engineering therapeutic bispecific antibodies using CrossMab technology
Christian Klein et al.
METHODS (2019)
The Burden of Macular Diseases in Central and Eastern Europe-Implications for Healthcare Systems
Polona Jaki Mekjavic et al.
VALUE IN HEALTH REGIONAL ISSUES (2019)
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Chloe J. Peach et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Diabetic Retinopathy: Pathophysiology and Treatments
Wei Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Qi Sheng You et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies
Jie-Hua Chen et al.
NUTRITION & METABOLISM (2018)
Diabetic macular edema: Evidence-based management
David J. Browning et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2018)
Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment
E. Al Kahtani et al.
EYE (2017)
Gene therapy for age-related macular degeneration
Nicholas A. Moore et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization
Veli-Matti Leppanen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation
Danny S. Ng et al.
SCIENTIFIC REPORTS (2017)
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY RETINA (2017)
Assessment of Neurotrophins and Inflammatory Mediators in Vitreous of Patients With Diabetic Retinopathy
Joseph D. Boss et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Joerg T. Regula et al.
EMBO MOLECULAR MEDICINE (2016)
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Christian Klein et al.
MABS (2016)
Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis
Bruce A. Corliss et al.
MICROCIRCULATION (2016)
Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2016)
Angiopoietin 2 induces astrocyte apoptosis via αvβ5-integrin signaling in diabetic retinopathy
J-H Yun et al.
CELL DEATH & DISEASE (2016)
Cellular and Molecular Pathology of Age-Related Macular Degeneration: Potential Role for Proteoglycans
Othman Al Gwairi et al.
JOURNAL OF OPHTHALMOLOGY (2016)
The clinical utility of aflibercept for diabetic macular edema
Michael W. Stewart
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
Deletion of Placental Growth Factor Prevents Diabetic Retinopathy and Is Associated With Akt Activation and HIF1 alpha-VEGF Pathway Inhibition
Hu Huang et al.
DIABETES (2015)
Angiopoietin 2 Induces Pericyte Apoptosis via α3β1 Integrin Signaling in Diabetic Retinopathy
Sung Wook Park et al.
DIABETES (2014)
Intravitreal Aflibercept for Diabetic Macular Edema
Jean-Francois Korobelnik et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Elena Beltramo et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Intravitreal aflibercept for neovascular age-related macular degeneration
David Xu et al.
IMMUNOTHERAPY (2013)
Aflibercept in wet AMD: specific role and optimal use
F. Semeraro et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Diana V. Do et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
9 Aflibercept in wet age-related macular degeneration: a perspective review
Matthew Ohr et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2012)
Prevention of Experimental Choroidal Neovascularization and Resolution of Active Lesions by VEGF Trap in Nonhuman Primates
T. Michael Nork et al.
ARCHIVES OF OPHTHALMOLOGY (2011)
Comparing protein VEGF inhibitors: In vitro biological studies
Lanlan Yu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration
David M. Brown et al.
OPHTHALMOLOGY (2011)
The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema
Diana V. Do et al.
OPHTHALMOLOGY (2011)
The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2011)
Expression and Role of VEGF in the Adult Retinal Pigment Epithelium
Knatokie M. Ford et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
A Subretinal Matrigel Rat Choroidal Neovascularization (CNV) Model and Inhibition of CNV and Associated Inflammation and Fibrosis by VEGF Trap
Jingtai Cao et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema
D. V. Do et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2009)
A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2009)
The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII The Twenty-Five-Year Progression of Retinopathy in Persons with Type 1 Diabetes
Ronald Klein et al.
OPHTHALMOLOGY (2008)
Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Muller Cells and Photoreceptors
Magali Saint-Geniez et al.
PLOS ONE (2008)
Reactive changes of retinal astrocytes and Muller glial cells in kainate-induced neuroexcitotoxicity
Min-Lin Chang et al.
JOURNAL OF ANATOMY (2007)
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2006)
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy
D Watanabe et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2005)
Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor
Y Oshima et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization
JM Rakic et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier
Y Saishin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
Molecular mechanism and role of endothelial monocyte chemoattractant protein-1 induction by vascular endothelial growth factor
M Yamada et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Share Paper
